Mindset Pharma Inc (CSE:MSET) (OTCQB:MSSTF) (FRA:9DF) has announced the appointment of Dr Ishrat Husain to the company’s scientific advisory board.
Mindset said Dr Husain will provide strategic guidance as the company develops a regulatory pathway for its novel psychedelic-based therapeutics to receive US Food and Drug Administration (FDA) approval and eventually offer relief to patients suffering from mental illness.
“Dr Husain brings an important perspective and skillset to Mindset with his experience developing clinical trials for emerging treatments for mood disorders, as well as his first-hand clinical knowledge as an active psychiatrist,” Mindset Pharma CEO James Lanthier said in a statement.
READ: Mindset Pharma leading the charge to advance psychedelic medicines to treat mental illness
“He will help position us for success as we move through the regulatory process and eventually into the clinic,” Lanthier added.
“Dr Husain’s appointment is another important milestone in our journey to bring safer, more efficacious psychedelic-inspired mental illness treatments to the market.”
Mindset noted that Dr Husain has published more than 40 research papers investigating the neurobiology and associated clinical care of mood disorders and is currently conducting clinical trials of emerging treatments for these conditions.
Based in Toronto, Mindset Pharma is focused on creating optimized and patentable next-generation psychedelic medicines across its four novel families of psychedelic-inspired compounds to treat neurological and psychiatric disorders.
Contact Sean at sean@proactiveinvestors.com